Introduction {#s1}
============

Recent pharmaceutical research and development (R&D) reports show that the probability of success for a new pharmaceutical compound to get to the market has declined in the last 10 years (Pammolli et al., [@B92]). The average time of drug development has increased from 9.7 years during the 1990s to 13.9 years from 2000 onwards. The average probability of success of total numbers of R&D projects in the cardiovascular system is only 4.86%. Drug repositioning, new use of old drugs, can shorten the development time and provide solutions for the high cost and declined number of new successful drugs of the pharmaceutical companies (Dudley et al., [@B35]). Computational repositioning strategies can predict new therapeutic indications for FDA-approved drugs, which then have to undergo clinical trials for the new indication (Belch et al., [@B10]; Ostchega et al., [@B91]; Shameer et al., [@B110]). In this study, we primarily use the network-based approach in computational drug repositioning.

Peripheral arterial disease (PAD) results from atherosclerosis, the plaque built-up inside the arteries, which blocks the blood flow in the peripheral arteries and most commonly in the arteries that perfuse the legs (Belch et al., [@B10]; Annex, [@B4]). Age, diabetes, and cigarette smoking are the major risk factors for the development of PAD (Belch et al., [@B10]; Ostchega et al., [@B91]; Annex, [@B4]). There are 8--12 million people with PAD in the United States (Writing Group et al., [@B131]). The clinical manifestations of PAD range from patients who do not report leg pain but have a lower functional capacity (approximately 50% of all PAD subjects) to patients who have intermittent claudication manifested as leg pain with walking/exercise that is relieved with rest (approximately 33--40% of all PAD subjects) (Hirsch et al., [@B60]; Norgren et al., [@B90]). With the goal to increase blood flow around blockages, clinical trials using drugs and gene delivery for therapeutic angiogenesis such as VEGF (vascular endothelial growth factor) gene delivery have been performed for the last two decades but have not been successful.

Hoier et al. showed that there was no difference in basal skeletal muscle VEGF mRNA content before and after passive or active exercise between PAD patients and control (Hoier et al., [@B61]). However, the basal level of anti-angiogenic protein thrombospondin-1 (TSP1) was remarkably higher in the PAD patients than control groups. They conclude that the anti-angiogenic factors dominate the pro-angiogenic factors in PAD patients. The up-regulation of TSP1 has been shown in various gene expression microarray studies of mouse (Chu et al., [@B25]) and human samples of PAD (Fu et al., [@B46]; Masud et al., [@B83]). Currently there are no FDA-approved drugs targeting TSP1. Therefore, the computational drug repositioning approach to predict the drugs targeting other endogenous anti-angiogenic proteins should be helpful for designing clinical trials for therapeutic angiogenesis in PAD.

Inflammation plays an important role in initiation and progression of PAD, and many circulating biomarkers such as matrix metalloproteinases (MMPs) and interleukin are considered as the clinical manifestation of PAD (Signorelli et al., [@B115]). Atherosclerosis is the dominant cause of many cardiovascular diseases, including myocardial infarction, heart failure, coronary artery disease (CAD), and stroke (Frostegård, [@B44]). Atherosclerosis is a chronic inflammatory condition. Potential anti-inflammatory treatments in atherosclerosis are reviewed in Frostegård ([@B44]). The interplay between inflammation and endothelial progenitor cells is critical in cardiovascular diseases (Grisar et al., [@B52]). Combination of anti-inflammatory and pro-angiogenic treatments for PAD was suggested and validated *in vivo* by Zachman et al. ([@B136]). However, a systematic bioinformatics approach to identify the potential drug repositioning for inhibition of anti-angiogenic and pro-inflammatory proteins for PAD is still lacking.

We previously constructed the PADPIN, protein-protein interaction network (PIN) in PAD that includes angiome, immunome, and arteriome, characterizing the processes of angiogenesis, immune response/inflammation and arteriogenesis, respectively (Chu et al., [@B25]). We have analyzed several available microarray gene expression datasets from ischemic and non-ischemic muscles in two mouse models of PAD (in C57BL/6 and BALB/c mouse species) from Hazarika et al. ([@B56]) to identify important genes/proteins in PAD, such as THBS1 (thrombospondin-1), TLR4 (toll-like receptor 4), EphA4 (EPH receptor A4), and TSPAN7 (tetraspanin 7). However, none of the four genes (THBS1, TLR4, EphA4, and TSPAN7) have FDA-approved drugs to target them. Considering the time (\>10 years) and cost (\>\$1 billion) for developing a new drug agent, drug repositioning in PAD offers promise of providing effective therapeutics in shorter time and at lower cost compared to conventional *de-novo* drug discovery and development. In addition, drug repurposing is an approach of taking agents in development that have achieved adequate safety for one indication but are tested for efficacy in another when safety is already evident.

Materials and methods {#s2}
=====================

Resources for drugs and drug-target interactions
------------------------------------------------

We rely on two major resources for drug information and drug-target, DrugBank 3.0 <http://www.drugbank.ca/> (Knox et al., [@B71]) and Pharmacogenomics Knowledge Base (PharmGKB) <http://www.pharmgkb.org/> (Whirl-Carrillo et al., [@B128]). DrugBank contains extensive omics data, such as pharmacogenomic, pharmacoproteomic, and pharmacometabolomic data. We use DTome (Drug-Target interactome tool) (Sun et al., [@B118]) to compile all the drugs included in DrugBank 3.0 (Knox et al., [@B71]), including the approved, experimental, nutraceutical, illicit, and withdrawn drugs. We compile three binary relations in DrugBank from DTome: drug-drug, drug-gene, and drug-target interactions. This compilation provides the rich resources for the potential repositioning or repurposing. By considering the drug safety and development time, we focus on FDA-approved drugs in this study. We compiled the three binary relations from PharmGKB: gene-disease, gene-drug, and gene-gene interactions. The drug-target interactions were compiled from both DrugBank (Knox et al., [@B71]) and PharmGKB (Whirl-Carrillo et al., [@B128]).

Proteins in PADPIN and therapeutic angiogenesis in PAD
------------------------------------------------------

Details of the construction of PADPIN, protein-protein interaction (PIN) of PAD in angiogenesis, immune response and arteriogenesis, are described inChu et al. ([@B25]). The methodology is similar to that used for constructing the global PIN of angiogenesis (angiome) that comprises 1233 proteins and 5726 interactions (Chu et al., [@B24]). The PIN of immune response (immunome) comprises 3490 proteins and 21,164 interactions. The PIN of arteriogenesis (arteriome) comprises 289 proteins and 803 interactions. The degree of node represents the number of links to a node in the network. The network parameter was calculated by NetworkAnalyzer (Assenov et al., [@B5]) in Cytoscape (Smoot et al., [@B116]). We start with the genes listed in the three PINs, to find the interactive drugs from the DrugBank and PharmGKB. Note that in bioinformatics publications, and specifically in protein-protein networks publications, the terms "gene" and "protein" are sometimes used interchangeably; while we mostly use "protein" term in this context, we sometime use "gene" to be consistent with previous publications.

List of anti-angiogenic and pro-inflammatory genes
--------------------------------------------------

The activation of a specific biological process can be implemented using two strategies. One is direct activation of the genes involved in positive regulation of that biological process; the other is inhibition of the genes involved in negative regulation of that biological process. Specifically for PAD, to stimulate vascular growth and remodeling and increase the blood flow, we propose inhibition of genes annotated as negative regulation of angiogenesis as a therapeutic approach to stimulating angiogenesis. The rationale for this approach is that numerous clinical trials aimed at stimulating angiogenesis by growth factors such as VEGF-A and FGF-2 have not been successful. We identified 39 anti-angiogenic genes, chosen by Gene Ontology (GO: 0016525) and literature (Chu et al., [@B23]). The endothelial dysfunction in patients with PAD is characterized by impaired nitric oxide signaling, excessive inflammation and diminished response to angiogenic factors (Annex, [@B4]). To inhibit the inflammation, we propose inhibition of pro-inflammatory responses as a therapeutic approach for anti-inflammatory treatment of PAD. There are 89 genes classified in positive regulation of inflammatory response (GO:0050729). We list these genes in Table [1](#T1){ref-type="table"}.

###### 

**List of 39 anti-angiogenic and 89 pro-inflammatory genes**.

  **Categories**     **Gene ontology**                                           **List of genes**
  ------------------ ----------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Anti-angiogenic    Negative regulation of angiogenesis (GO: 0016525)           AMOT, ANGPT2, APOH, BAI1, CCL2, CCR2, COL4A2, COL4A3, CXCL10, FASLG, FOXO4, GHRL, GTF2I, HDAC5, HHEX, HOXA5, HRG, KLF4, KLK3, KRIT1, LECT1, LIF, MAP2K5, NF1, NPPB, NPR1, PDE3B, PF4, PML, PTPRM, ROCK1, ROCK2, SERPINE1, SERPINF1, STAB1, THBS1, THBS2, THBS4, TIE1
  Pro-inflammatory   Positive regulation of inflammatory response (GO:0050729)   ACE, ADAM8, ADORA2B, ADORA3, AGER, AGT, AGTR1, ALOX5AP, AOC3, C3, CCL24, CCL3, CCL3L3, CCL5, CCR2, CCR5, CCR7, CD28, CD47, CLOCK, CNR1, CTSS, CX3CL1, EDNRA, EGFR, FABP4, FCER1A, FCER1G, FCGR1A, FCGR2A, FFAR3, GPRC5B, HSPD1, HYAL2, IDO1, IL12B, IL15, IL18, IL1B, IL1RL1, IL2, IL21, IL23A, IL33, IL6, IL6ST, ITGA2, JAK2, LBP, LTA, MAPK13, MIF, NLRP12, NPY5R, OSM, OSMR, PDE2A, PDE5A, PIK3CG, PLA2G2A, PLA2G4A, PLA2G7, PRKCA, PTGER3, PTGER4, PTGS2, RPS19, S100A12, S100A8, S100A9, SERPINE1, STAT5A, STAT5B, TAC1, TGM2, TLR2, TLR3, TLR4, TLR7, TLR9, TLR10, TNF, TNFRSF11A, TNFRSF1A, TNFSF11, TNFSF4, TNIP1, WNT5A, ZP3

Results {#s3}
=======

Drug-targets relations in angiome, immunome and arteriome of PADPIN
-------------------------------------------------------------------

We collected 11,043 binary relations between the drug and drug targets from DrugBank 3.0 (Knox et al., [@B71]) and 3138 binary relations between the drug and associated genes of that drug, which may not be the direct targets, from PharmGKB (Whirl-Carrillo et al., [@B128]). By matching the genes in angiome, immunome, and arteriome with the drug targets listed in the drug-gene binary relations from DrugBank and PharmGKB, we build the complete tables of genes and repositioning drugs (Tables [S1](#SM1){ref-type="supplementary-material"}--[S3](#SM3){ref-type="supplementary-material"}). Table [S1](#SM1){ref-type="supplementary-material"} shows 409 and 174 drug targets listed in angiome for the drugs from DrugBank and PharmGKB, respectively. We select the genes with at least one drug targeting that gene in angiome, and skip the genes without any drug-gene relations. There might be multiple drugs targeting the same drug target; we list the multiple drugs in the same row of the table. Table [S2](#SM2){ref-type="supplementary-material"} shows 865 and 382 drug targets in immunome for the drugs from DrugBank and PharmGKB, respectively. Table [S3](#SM3){ref-type="supplementary-material"} shows 82 and 46 drug targets in arteriome for the drugs from DrugBank and PharmGKB, respectively.

We rank the genes in angiome, immunome, and arteriome by the degree of nodes, i.e., number of links of the nodes in the network, in Tables [S1](#SM1){ref-type="supplementary-material"}--[S3](#SM3){ref-type="supplementary-material"}, respectively. Tables [S1](#SM1){ref-type="supplementary-material"}--[S3](#SM3){ref-type="supplementary-material"} provide the complete list of drugs and drug targets which are annotated in angiogenesis, immune response/inflammation, and arteriogenesis. Tables [S1](#SM1){ref-type="supplementary-material"}--[S3](#SM3){ref-type="supplementary-material"} provide the complete list of drugs in DrugBank and PharmGKB, including approved, experimental, nutraceutical, illicit, and withdrawn drugs. Considering the drug safety and efficacy issues, we mostly consider the FDA-approved drugs in the predictions of repositioning drugs (Table [S4](#SM4){ref-type="supplementary-material"}).

Inhibition of anti-angiogenic pro-inflammatory genes
----------------------------------------------------

We postulate two strategies to the PAD treatment: pro-angiogenic and anti-inflammatory. Starting from the 39 genes annotated in negative regulation of angiogenesis (see Materials and Methods), we match the genes with drug targets and drugs listed in Table [S1](#SM1){ref-type="supplementary-material"}, and only list the FDA-approved drugs from DrugBank in Table [2](#T2){ref-type="table"}. The five genes are CCL2, NPPB, NPR1, PF4, and SERPINE1. These drugs include mimosine targeting CCL2, carvedilol targeting NPPB, nitroprusside targeting NPR1, urokinase, reteplase, and drotrecogin alfa targeting SERPINE1. The beta-blockers (e.g., carvedilol in our prediction) in general have not been shown to affect PAD symptoms, but they do not make PAD symptoms worse (Paravastu et al., [@B95]). Infusion of recombinant-based plasminogen activator (e.g., reteplase) and urokinase can clear blood clots and restore blood flow in occluded blood vessels of patients with diseases such as myocardial infarction and PAD (Lippi et al., [@B78]). The mechanism of mimosine targeting CCL2 in PAD is not clear.

###### 

**Predictions of pro-angiogenic FDA-approved drugs that target anti-angiogenic genes**.

  **Gene symbol**   **Gene name**                                                                                   **DrugBank**                                                                                            **Physiological relevance in PAD or CAD**
  ----------------- ----------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------
  CCL2              Chemokine (C-C motif) ligand 2                                                                  Mimosine, danazol                                                                                       Potential indicator of atherosclerosis in PAD (Rull et al., [@B106])
  NPPB              Natriuretic peptide B                                                                           Carvedilol                                                                                              Three SNPs at NPPB locus associated with lower risk of PAD (Hu et al., [@B65])
  NPR1              Natriuretic peptide receptor 1                                                                  Nitroprusside, nitroglycerin, isosorbide dinitrate, amyl nitrite, erythrityl tetranitrate, nesiritide   
  PF4               Platelet factor 4                                                                               Drotrecogin alfa                                                                                        PF4 level increasing in patients with coronary artery ectasia (Yasar et al., [@B134])
  SERPINE1          Serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1   Alteplase, urokinase, reteplase, anistreplase, tenecteplase, drotrecogin alfa                           Plasminogen activator inhibitor-1 (PAI-1) increasing in patients with CLI (critical limb ischemia), leading to prothrombotic (Björck et al., [@B12])

These anti-angiogenic proteins may not have direct physiological relevance in PAD. We use PubMed by searching the keywords "(Gene symbol) AND (PAD OR coronary arterial disease)" to find the relevant literature in the recent 10 years (2005--2015) for the five genes in PAD. These references support the potential biomarkers or drug targets of the five anti-angiogenic proteins in PAD, such as CCL2 (Rull et al., [@B106]), NPPB (Hu et al., [@B65]), and SERPINE1 (Yasar et al., [@B134]). However, these references do not link the anti-angiogenic properties of these genes to PAD. Thus, the concept of inhibition of anti-angiogenic proteins in PAD is novel and should be further explored.

Inhibition of pro-inflammatory genes
------------------------------------

We match the 89 pro-inflammatory genes with drug targets and drugs listed in Table [S2](#SM2){ref-type="supplementary-material"}, and only list the FDA-approved drugs from DrugBank in Table [3](#T3){ref-type="table"} (see the list of pro-inflammatory genes in Methods). The corresponding FDA-approved drugs include maraviroc (an antiretroviral drug, a CCR5 inhibitor), bosentan (a dual endothelin receptor antagonist that affects both endothelin A and B receptors, used in the treatment of pulmonary artery hypertension), sitaxentan (endothelin A receptor antagonist, used in the treatment of pulmonary artery hypertension), cetuximab (EGFR antagonist, used in several types of cancer) and imiquimod (an immune response modulator, used for skin diseases including skin cancer).

###### 

**Predictions of anti-inflammatory FDA-approved drugs that target pro-inflammatory genes**.

  **Gene symbol**   **Description**                                                                                 **DrugBank**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 **Physiological relevance in PAD or CAD**
  ----------------- ----------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ACE               Angiotensin I converting enzyme                                                                 Ramipril, fosinopril, trandolapril, benazepril, enalapril, candoxatril, moexipril, lisinopril, perindopril, quinapril, rescinnamine, captopril, cilazapril, spirapril                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ACE inhibitor helping the walking ability in patients with CLI, but not improving ABI (ankle-pressure index) (Hunter et al., [@B66]; Shahin et al., [@B109])
  ADORA2B           Adenosine A2b receptor                                                                          Theophylline, adenosine, enprofylline, defibrotide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  AGTR1             Angiotensin II receptor, type 1                                                                 Valsartan, olmesartan, losartan, candesartan, eprosartan, telmisartan, irbesartan, forasartan, saprisartan, tasosartan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Correlation between the increased AGTR1 and cardiovascular risk factors (Baños et al., [@B8])
  AOC3              Amine oxidase, copper containing 3                                                              Phenelzine, hydralazine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  C3                Complement component 3                                                                          Intravenous immunoglobulin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   C3 level in serum associated with ABI and atherosclerosis in PAD patients (Fehervari et al., [@B39])
  CCR5              Chemokine (C-C motif) receptor 5                                                                Maraviroc                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    A treatment target in pulmonary arterial hypertension (Amsellem et al., [@B3])
  CNR1              Cannabinoid receptor 1 (brain)                                                                  Dronabinol, nabilone, rimonabant, dronabinol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  EDNRA             Endothelin receptor type A                                                                      Bosentan, sitaxentan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  EGFR              Epidermal growth factor receptor                                                                Cetuximab, trastuzumab, lidocaine, gefitinib, erlotinib, lapatinib, panitumumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  FCER1A            Fc fragment of IgE, high affinity I, receptor for; alpha polypeptide                            Omalizumab, benzylpenicilloyl polylysine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  FCER1G            Fc receptor, IgE, high affinity I, gamma polypeptide                                            Benzylpenicilloyl polylysine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  FCGR1A            Fc fragment of IgG, high affinity Ia, receptor (CD64)                                           Cetuximab, etanercept, intravenous immunoglobulin, adalimumab, abciximab, gemtuzumab ozogamicin, trastuzumab, rituximab, basiliximab, muromonab, ibritumomab, tositumomab, alemtuzumab, alefacept, efalizumab, natalizumab, palivizumab, daclizumab, bevacizumab, porfimer                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  FCGR2A            Fc fragment of IgG, low affinity IIa, receptor (CD32)                                           Cetuximab, etanercept, intravenous immunoglobulin, adalimumab, abciximab, gemtuzumab ozogamicin, trastuzumab, rituximab, basiliximab, muromonab, ibritumomab, tositumomab, alemtuzumab, alefacept, efalizumab, natalizumab, palivizumab, daclizumab, bevacizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  IL1B              Interleukin 1, beta                                                                             Minocycline, gallium nitrate, canakinumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  IL6               Interleukin 6                                                                                   Ginseng                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Phase III clinical trial targeting IL-6 by tocilizumab in cardiovascular disease (Ridker and Lüscher, [@B101])
  LTA               Lymphotoxin alpha                                                                               Etanercept                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Implicated in predisposition for heart attack by genome-wide association studies (GWAS) (Topol et al., [@B123])
  PDE5A             phosphodiesterase 5A, cGMP-specific                                                             Sildenafil, theophylline, pentoxifylline, tadalafil, vardenafil, dipyridamole, udenafil                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      PDE5 inhibition promotes ischemia-induced angiogenesis (Sahara et al., [@B107])
  PLA2G2A           Phospholipase A2, group IIA (platelets, synovial fluid)                                         Indomethacin, diclofenac, ginkgo biloba, suramin, ginkgo biloba                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  PLA2G4A           Phospholipase A2, group IVA (cytosolic, calcium-dependent)                                      Fluticasone propionate, quinacrine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  PRKCA             Protein kinase C, alpha                                                                         Phosphatidylserine, vitamin E                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                The key protein in regulation of platelet function and thrombosis in arteries (Konopatskaya and Poole, [@B72])
  PTGER3            Prostaglandin E receptor 3 (subtype EP3)                                                        Bimatoprost, dinoprostone, misoprostol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  PTGS2             Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase)           Gamma-homolinolenic acid, icosapent, aminosalicylic acid, mesalazine, acetaminophen, indomethacin, nabumetone, ketorolac, tenoxicam, lenalidomide, celecoxib, tolmetin, piroxicam, fenoprofen, diclofenac, sulindac, flurbiprofen, etodolac, mefenamic acid, naproxen, sulfasalazine, phenylbutazone, meloxicam, carprofen, diflunisal, suprofen, salicyclic acid, meclofenamic acid, acetylsalicylic acid, bromfenac, oxaprozin, ketoprofen, balsalazide, thalidomide, ibuprofen, lumiracoxib, magnesium salicylate, salicylate-sodium, salsalate, trisalicylate-choline, ginseng, antrafenine, antipyrine, tiaprofenic acid, etoricoxib, niflumic acid, lornoxicam, nepafenac, gamma-homolinolenic acid, icosapent, ginseng, thalidomide   PTGS2 (COX2) inhibition improves inflammation and endothelial dysfunction in PAD patients with intermittent claudication (IC) (Flórez et al., [@B41])
  S100A12           S100 calcium binding protein A12                                                                Olopatadine, amlexanox                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       The potential biomarker for chronic arterial disease (Saito et al., [@B108]) and associated with PAD (Shiotsu et al., [@B113])
  SERPINE1          Serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1   Alteplase, urokinase, reteplase, anistreplase, tenecteplase, drotrecogin alfa                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Level of plasminogen activator inhibitor-1 (PAI-1) increased in patients with CLI (critical limb ischemia) (Björck et al., [@B12])
  STAT5B            Signal transducer and activator of transcription 5B                                             Dasatinib                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  TLR2              Toll-like receptor 2                                                                            Ospa lipoprotein                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             TLR2 and TLR4 expression increase during atherosclerosis, but only TLR4 gene expression associated with PAD (Varela et al., [@B124])
  TLR7              Toll-like receptor 7                                                                            Imiquimod, hydroxychloroquine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  TLR9              Toll-like receptor 9                                                                            Chloroquine, hydroxychloroquine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  TNF               Tumor necrosis factor                                                                           Etanercept, adalimumab, infliximab, chloroquine, thalidomide, glucosamine, clenbuterol, pranlukast, amrinone, thalidomide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Circulating TNF higher in PAD patients than control (Gardner et al., [@B48]); Circulating cytokines induce endothelial dysfunction in PAD patients (Botti et al., [@B13]); Negative correlation between TNF concentration and pain free walking distance (Wozniak et al., [@B130])
  TNFSF11           Tumor necrosis factor (ligand) superfamily, member 11                                           Lenalidomide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

To find the physiological relevance of these pro-inflammatory genes in PAD, we continue to use PubMed to find the relevant references. References in Table [3](#T3){ref-type="table"} support our hypothesis that anti-inflammatory drugs have high potential for repositioning for PAD. Some drugs cannot improve ABI (ankle-pressure index) of PAD patients but can improve the walking ability in patients with critical limb ischemia (CLI), such as ACE inhibitors (Hunter et al., [@B66]; Shahin et al., [@B109]). Some genes are indicated as related with PAD, such as C3 (complement component 3) (Fehervari et al., [@B39]), PTGS2 (prostaglandin-endoperoxide synthase 2) (Flórez et al., [@B41]), SERPINE1 (Björck et al., [@B12]), S100A12 (Shiotsu et al., [@B113]), and TNF (Botti et al., [@B13]; Wozniak et al., [@B130]; Gardner et al., [@B48]). Some genes are potential biomarkers or associated with other cardiovascular diseases, such as AGTR1 (angiotensin II receptor, type 1) in coronary occlusive disease (Baños et al., [@B8]), CCR5 in pulmonary arterial hypertension (Amsellem et al., [@B3]), LTA (lymphotoxin alpha) in CAD (Topol et al., [@B123]), and PRKCA (protein kinase C, alpha) in atherosclerosis (Konopatskaya and Poole, [@B72]). Many of the anti-inflammatory genes in Table [3](#T3){ref-type="table"} are not directly associated with PAD or CAD based on PubMed search, such as ADORA2B (adenosine A2b receptor), EDNRA (endothelin receptor type A), FCER1G (Fc receptor, IgE, high affinity I, gamma polypeptide), STAT5B (signal transducer and activator of transcription 5B), and TLR9 (toll-like receptor 9). In general, the physiological evidence of these anti-inflammatory genes listed in Table [3](#T3){ref-type="table"} strongly supports our hypothesis that inhibition of pro-inflammatory genes is a viable drug repositioning strategy in PAD.

Visualization of drug-target network
------------------------------------

Graph representation is used to visualize pro-angiogenic and anti-inflammatory repositioning drugs for PAD in Figures [1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}, respectively. We plot the drug-target networks of the anti-angiogenic and pro-inflammatory proteins for the drugs in Tables [2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}, respectively. We represent the drug target by pink circle and the drug by blue square. Figure [1](#F1){ref-type="fig"} shows several compounds targeting the proteins which are annotated as negative regulation of angiogenesis. Figure [2](#F2){ref-type="fig"} shows the drug-target networks of the anti-inflammatory drugs and targets from Table [3](#T3){ref-type="table"}. The number of inflammation targets and drugs in Figure [2](#F2){ref-type="fig"} is much larger than anti-angiogenic targets and drugs in Figure [1](#F1){ref-type="fig"}. This gives the insight for the development of clinical trials of anti-inflammatory drugs in PAD in the future. We will discuss the potential clinical trials in Discussion.

![**Pro-angiogenic drug-target interaction networks**.](fphar-06-00179-g0001){#F1}

![**Anti-inflammatory drug-target interaction networks**.](fphar-06-00179-g0002){#F2}

Discussion {#s4}
==========

The clinical trials aimed at stimulating VEGF in PAD and CAD have been unsuccessful (Annex, [@B4]). The exercise therapy has been demonstrated as the beneficial treatment for PAD, including walking tolerance, modified inflammatory markers, and adaptation of the limb (e.g., angiogenesis and arteriogenesis) (Haas et al., [@B53]). Clinical trials with agents targeting angiogenesis and inflammation, other than stimulation of VEGF, should be considered in the future. Below we provide insights for the potential repositioning drugs in PAD identified in this study, including the mechanism of action of these drugs, case studies for several selected drugs in clinical trials, and future experimental validations.

Mechanism of action of repositioning drugs for PAD
--------------------------------------------------

Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"} provide the anti-angiogenic and pro-inflammatory genes/proteins, drugs targeting these molecules, and physiological evidence for the involvement of these molecules in PAD. However, even though these drug-targets have been identified by our bioinformatics approaches, the mechanism of action of these drugs in PAD and the feasibility of the clinical trials need to be elucidated. Specifically, the effect of some of these drugs to promote angiogenesis in PAD by targeting anti-angiogenic proteins is unknown. Therefore, we search PubMed for the drugs listed in Table [2](#T2){ref-type="table"} using the keywords "(drug name) AND angiogenesis" to understand the mechanism and original use of these putative pro-angiogenic drugs. We list the drugs with at least one supporting reference found in PubMed in Table [4](#T4){ref-type="table"}. These drugs include beta-1 adrenergic receptors blocker (carvedilol, targeting NPPB), vasodilator (isosorbide dinitrate, targeting NPR1), and plasminogen activator (alteplase, targeting SERPINE1).

###### 

**Mechanism of Action and original use of the drugs for repositioning as pro-angiogenic in PAD**.

  **Drug name**          **Target in angiogenesis**   **Degree of target in angiome**   **Mechanism of action**                                                  **Original use**           **PubMed search**
  ---------------------- ---------------------------- --------------------------------- ------------------------------------------------------------------------ -------------------------- --------------------------------------------------
  Alteplase              SERPINE1                     14                                Plasminogen activator                                                    Acute ischemic stroke      Lapchak and Araujo, [@B74]; Hacke et al., [@B54]
  Danazol                CCL2                         12                                Synthetic steroid with antigonadotropic and anti-estrogenic activities   Endometriosis              Thomas et al., [@B122]; Szubert et al., [@B119]
  Nitroprusside          NPR1                         4                                 A source of nitric oxide, a potent peripheral vasodilator                Hypertensive emergency     Ziche et al., [@B137]; Pyriochou et al., [@B97]
  Isosorbide dinitrate   NPR1                         4                                 Vasodilator                                                              Angina pectoris            Goertz et al., [@B50]
  Nesiritide             NPR1                         4                                 Recombinant form of brain natriuretic peptide                            Heart failure              Shmilovich et al., [@B114]
  Carvedilol             NPPB                         3                                 Beta-1 and beta-2 adrenergic receptors blocker                           Congestive heart failure   Le et al., [@B75]; Stati et al., [@B117]

We further search PubMed for the anti-inflammatory drugs in Table [3](#T3){ref-type="table"} using the keywords "(drug name) AND inflammation" to elucidate the mechanism and original use of these anti-inflammatory drugs (Table [5](#T5){ref-type="table"}). These drugs include antiplatelet (abciximab targeting FCGR1A, acetylsalicylic acid targeting PTGS2), monoclonal antibody (adalimumab targeintg TNF-alpha), immune suppressant (alefacept targeting FCGR1A and FCGR2A), ACE inhibitor (benazepril, captopril and enalapril), non-steroidal anti-inflammatory drug (NSAID, e.g., bromfenac, celecoxib, diclofenac, ketorolac, nepafenac, sulindac), and PDE5 inhibitor (tadalafil, vardenafil).

###### 

**Mechanism of Action and original use of the drugs for repositioning as anti-inflammatory in PAD**.

  **Drug name**                    **Target in inflammation**   **Degree of target in immunome**   **Mechanism of action**                                                              **Original use**                                                                          **PubMed search**
  -------------------------------- ---------------------------- ---------------------------------- ------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------- -----------------------------------------------------
  Lapatinib                        EGFR                         137                                Tyrosine kinase inhibitor                                                            Breast cancer                                                                             Hall et al., [@B55]
  Lidocaine                        EGFR                         137                                Stopping nerves from sending pain signal                                             Local anesthetic and class-1b antiarrhythmic drug                                         Caracas et al., [@B17]
  Maraviroc                        CCR5                         46                                 CCR5 receptor antagonist class                                                       Human immunodeficiency virus (HIV) infection                                              Francisci et al., [@B43]
  Dasatinib                        STAT5B                       33                                 Bcr-Abl tyrosine kinase inhibitor                                                    Leukemia                                                                                  Futosi et al., [@B47]
  Chloroquine                      TNF, TLR9                    22, 22                             4-aminoquinoline drug                                                                Malaria, rheumatoid arthritis                                                             Yang et al., [@B133]
  Clenbuterol                      TNF                          22                                 Angiotensin-converting enzyme (ACE) inhibitor                                        Hypertension and heart failure                                                            Cudmore et al., [@B29]
  Glucosamine                      TNF                          22                                 Endogenous amino-monosaccharide synthesized from glucose                             Promoting joint and cartilage health                                                      Azuma et al., [@B6]; Chou et al., [@B22]
  Infliximab                       TNF                          22                                 Chimeric monoclonal antibody against TNF alpha                                       Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis                         Hirono et al., [@B59]
  Alteplase                        SERPINE1                     18                                 Plasminogen activator                                                                Acute ischemic stroke                                                                     Lapchak and Araujo, [@B74]; Hacke et al., [@B54]
  Intravenous immunoglobulin       C3, FCGR1A, FCGR2A           30, 13, 11                         IgG antibodies                                                                       Immune deficiencies, autoimmune diseases                                                  Nimmerjahn and Ravetch, [@B89]
  Drotrecogin alfa                 SERPINE1                     18                                 Recombinant form of human activated protein C                                        Decrease inflammation and the formation of blood clots in blood vessels                   Rice and Bernard, [@B100]
  Candesartan                      AGTR1                        16                                 Angiotensin II receptor antagonist                                                   High blood pressure and heart failure                                                     Yu et al., [@B135]
  Eprosartan                       AGTR1                        16                                 Angiotensin II receptor antagonist                                                   Treats high blood pressure                                                                Rahman et al., [@B98]
  Irbesartan                       AGTR1                        16                                 Angiotensin receptor blocker (ARB)                                                   High blood pressure                                                                       Taguchi et al., [@B120]
  Losartan                         AGTR1                        16                                 Angiotensin receptor blocker (ARB)                                                   High blood pressure                                                                       Merino et al., [@B84]
  Olmesartan                       AGTR1                        16                                 Angiotensin receptor blocker                                                         High blood pressure                                                                       Nagib et al., [@B87]
  Telmisartan                      AGTR1                        16                                 Angiotensin receptor blocker (ARB)                                                   High blood pressure                                                                       Al-Hejjaj et al., [@B2]
  Valsartan                        AGTR1                        16                                 Angiotensin receptor blocker (ARB)                                                   High blood pressure and heart failure                                                     Wang et al., [@B126]
  Adalimumab                       FCGR1A, FCGR2A, TNF          13, 11, 22                         Monoclonal antibody against TNF-alpha                                                Arthritis, ankylosing spondylitis                                                         Jiang et al., [@B68]
  Lenalidomide                     TNFSF11                      15                                 Immunomodulatory and antiangiogenic agent                                            Anemia and multiple myeloma                                                               Rozovski et al., [@B105]
  Thalidomide                      PTGS2, TNF                   7, 22                              Immunomodulatory drug                                                                Certain cancers, leprosy                                                                  Keifer et al., [@B70]
  Etanercept                       FCGR1A, FCGR2A, LTA, TNF     13, 11, 7, 22                      Tumor necrosis factor (TNF) inhibitor                                                Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis   Cao et al., [@B16]
  Abciximab                        FCGR1A, FCGR2A               13, 11                             Inhibits platelet aggregation by preventing the binding of fibrinogen                Patients undergoing percutaneous coronary intervention (PCI)                              Hong et al., [@B64]
  Alefacept                        FCGR1A, FCGR2A               13, 11                             Immune suppressant                                                                   Control of inflammation in moderate to severe psoriasis                                   Kraan et al., [@B73]; Chamian et al., [@B18]
  Alemtuzumab                      FCGR1A, FCGR2A               13, 11                             Binds to CD52, a protein present on the surface of mature lymphocytes                Chronic lymphocytic leukemia, multiple sclerosis                                          Heilman et al., [@B57]
  Daclizumab                       FCGR1A, FCGR2A               13, 11                             Monoclonal antibody binding to CD25, alpha subunit of the IL-2 receptor of T cells   Prevents rejection in organ transplantation, multiple sclerosis                           Papaliodis et al., [@B94]
  Efalizumab                       FCGR1A, FCGR2A               13, 11                             Immunosuppressant by inhibiting lymphocyte activation                                Psoriasis                                                                                 Pan et al., [@B93]
  Rituximab                        FCGR1A, FCGR2A               13, 11                             Monoclonal antibody against the protein CD20                                         Rheumatoid arthritis                                                                      Baslund et al., [@B9]
  Canakinumab                      IL1B                         10                                 Monoclonal antibody targeted at interleukin-1 beta                                   Rheumatoid arthritis, coronary artery disease                                             Ridker et al., [@B102]
  Gallium nitrate                  IL1B                         10                                 Gallium salt of nitric acid                                                          Symptomatic hypercalcemia                                                                 Eby, [@B36]
  Minocycline                      IL1B                         10                                 Bacteriostatic antibiotic                                                            Treats infections                                                                         Leite et al., [@B77]
  Aminosalicylic acid              PTGS2                        7                                  Inhibits folic acid synthesis and synthesis of the cell wall component               Tuberculosis                                                                              Williams et al., [@B129]
  Balsalazide                      PTGS2                        7                                  Converted in the body to mesalamine and reducing bowel inflammation                  Ulcerative colitis                                                                        Pardi et al., [@B96]
  Acetaminophen                    PTGS2                        7                                  Analgesics (pain relievers)                                                          Treats minor aches and pain and reduces fever                                             Jeon et al., [@B67]
  Acetylsalicylic acid (aspirin)   PTGS2                        7                                  Antiplatelet effect by inhibiting thromboxane                                        Prevention of arterial and venous thrombosis                                              Herová et al., [@B58]
  Bromfenac                        PTGS2                        7                                  Non-steroidal anti-inflammatory drug (NSAID)                                         Pain and swelling of the eye after cataract surgery                                       Rajpal et al., [@B99]
  Etodolac                         PTGS2                        7                                  Non-steroidal anti-inflammatory drug (NSAID)                                         Treats pain caused by arthritis                                                           Costa et al., [@B27]
  Etoricoxib                       PTGS2                        7                                  COX-2 selective inhibitor                                                            Rheumatoid arthritis, psoriatic arthritis, osteoarthritis                                 Moraes et al., [@B86]
  Gamma-homolinolenic acid         PTGS2                        7                                  Omega-6 fatty acid                                                                   Dietary supplement for a variety of human health problems                                 Kapoor and Huang, [@B69]
  Carprofen                        PTGS2                        7                                  Reduces inflammation by inhibition of COX-2                                          Pain and inflammation from arthritis                                                      Fox and Johnston, [@B42]
  Celecoxib                        PTGS2                        7                                  COX-2 selective non-steroidal anti-inflammatory drug (NSAID)                         Treats pain caused by arthritis                                                           Chen et al., [@B19]
  Ibuprofen                        PTGS2                        7                                  Non-steroidal anti-inflammatory drug (NSAID)                                         Pain and fever                                                                            Chmiel et al., [@B20]
  Ketoprofen                       PTGS2                        7                                  Non-steroidal anti-inflammatory drugs (NSAIDs)                                       Relief of pain and inflammation such as in rheumatic disease                              Choi et al., [@B21]
  Ketorolac                        PTGS2                        7                                  Non-steroidal anti-inflammatory drugs (NSAIDs)                                       Pain and inflammation caused by arthritis                                                 Donnenfeld et al., [@B34]
  Lornoxicam                       PTGS2                        7                                  Non-steroidal anti-inflammatory drug                                                 Pain, especially resulting from inflammatory diseases                                     Buritova and Besson, [@B14], [@B15]
  Mefenamic acid                   PTGS2                        7                                  Non-steroidal anti-inflammatory drug (NSAID)                                         Pain                                                                                      Cunha et al., [@B30]
  Meloxicam                        PTGS2                        7                                  Non-steroidal anti-inflammatory drug (NSAID)                                         Pain                                                                                      
  Mesalazine                       PTGS2                        7                                  5-amino-2-hydroxybenzoic acid                                                        Inflammatory bowel disease, such as ulcerative colitis                                    
  Nabumetone                       PTGS2                        7                                  Non-steroidal anti-inflammatory drug (NSAID)                                         Relief of pain and inflammation in arthritis                                              
  Naproxen                         PTGS2                        7                                  Non-steroidal anti-inflammatory drugs (NSAIDs)                                       Relief of pain, fever, swelling, and stiffness                                            
  Nepafenac                        PTGS2                        7                                  Non-steroidal anti-inflammatory drugs (NSAIDs)                                       Eye pain and swelling after cataract surgery                                              Nardi et al., [@B88]
  Niflumic acid                    PTGS2                        7                                  Inhibitor of cyclooxygenase-2                                                        Joint and muscular pain                                                                   Bilecen et al., [@B11]
  Piroxicam                        PTGS2                        7                                  Non-steroidal anti-inflammatory drugs (NSAIDs)                                       Pain, including arthritis pain                                                            
  Salsalate                        PTGS2                        7                                  Non-steroidal anti-inflammatory drugs (NSAIDs)                                       Rheumatoid arthritis                                                                      Goldfine et al., [@B51]
  Sulindac                         PTGS2                        7                                  Non-steroidal anti-inflammatory drug (NSAID)                                         Treats pain caused by arthritis, gout, or sore tendons                                    Mladenova et al., [@B85]
  Tenoxicam                        PTGS2                        7                                  Non-steroidal anti-inflammatory drug (NSAID)                                         Relieve inflammation and pain associated with rheumatoid arthritis                        
  Indomethacin                     PTGS2, PLA2G2A               7, 6                               Non-steroidal anti-inflammatory drugs (NSAIDs)                                       Reduce fever, pain, stiffness, and swelling                                               Glaser et al., [@B49]
  Suramin                          PLA2G2A                      6                                  Antimicrobial drug                                                                   Protozoa, Helminthiasis                                                                   Shiono et al., [@B112]; Liu et al., [@B79]
  Bosentan                         EDNRA                        4                                  Dual endothelin receptor antagonist                                                  Pulmonary artery hypertension                                                             Shetty and Derk, [@B111]
  Omalizumab                       FCER1A                       3                                  Reduce sensitivity to inhaled or ingested allergens                                  Asthma                                                                                    Holgate et al., [@B62], [@B63]
  Enazepril                        ACE                          2                                  Angiotensin-converting enzyme (ACE) inhibitor                                        High blood pressure                                                                       Yan et al., [@B132]
  Captopril                        ACE                          2                                  Angiotensin-converting enzyme (ACE) inhibitor                                        High blood pressure and heart failure                                                     El Desoky, [@B38]
  Dinoprostone                     PTGER3                       2                                  Prostaglandin E2 (PGE2)                                                              Helps dilate the opening of the uterus (cervix) in a pregnant woman                       Tang et al., [@B121]
  Dipyridamole                     PDE5A                        2                                  Inhibits the phosphodiesterase enzymes, coronary vasodilator                         Inhibits thrombus formation                                                               Weyrich et al., [@B127]; Massaro et al., [@B82]
  Enalapril                        ACE                          2                                  Angiotensin converting enzyme (ACE) inhibitors                                       Treats high blood pressure                                                                da Cunha et al., [@B31]
  Misoprostol                      PTGER3                       2                                  Non-steroidal anti-inflammatory drugs (NSAIDs)                                       Prevents stomach ulcers                                                                   Rossetti et al., [@B103]
  Pentoxifylline                   PDE5A                        2                                  Phosphodiesterase inhibiton                                                          Treating intermittent claudication resulting from peripheral artery disease               Abdel-Salam et al., [@B1]; Fernandes et al., [@B40]
  Perindopril                      ACE                          2                                  ACE inhibitor                                                                        Treats high blood pressure and coronary artery disease                                    Rowbotham et al., [@B104]
  Quinapril                        ACE                          2                                  ACE inhibitor                                                                        High blood pressure and heart failure                                                     Egido and Ruiz-Ortega, [@B37]
  Bildenafil                       PDE5A                        2                                  Inhibiting cGMP-specific phosphodiesterase type 5                                    Erectile dysfunction, pulmonary arterial hypertension                                     de Visser et al., [@B33]
  Tadalafil                        PDE5A                        2                                  PDE5 inhibitor                                                                       Erectile dysfunction, benign prostatic hyperplasia, pulmonary arterial hypertension       Varma et al., [@B125]
  Theophylline                     PDE5A, ADORA2B               2, 2                               Methylxanthine drug                                                                  Asthma and respiratory disease                                                            Cosio et al., [@B26]
  Vardenafil                       PDE5A                        2                                  PDE5 inhibitor                                                                       Erectile dysfunction                                                                      Lubamba et al., [@B80]
  Hydralazine                      AOC3                         1                                  Vasodilator                                                                          Treats high blood pressure and heart failure                                              Bai et al., [@B7]

Case studies of potential drug targets and drug repositioning in PAD
--------------------------------------------------------------------

We choose three candidate drugs for repositioning in PAD as case studies of our predictions. We selected several drugs that are anti-inflammatory or pro-angiogenic and had no effects on each other. These drugs include bosentan, carvedilol, and maraviroc. We compared the drug targets with the up-regulated genes in the microarray dataset of PAD, including the mouse data of Hazarika et al. ([@B56]), and human microarray studies of Masud et al. ([@B83]), Fu et al. ([@B46]), and Croner et al. ([@B28]).

### Case I: Bosentan targeting EDNRA

The endothelin receptor antagonists (bosentan and ambrisentan) have been approved for use in pulmonary arterial hypertension (PAH) and have been assigned orphan drug status. Details of hepatotoxicity of bosentan, ambrisentan, and sitaxentan are reviewed in de Haro Miralles et al. ([@B32]). Endothelin-1 is a powerful endogenous vasoconstrictor (Frumkin, [@B45]) and thus blocking endothelin could improve perfusion to the lower extremities in patients with PAD. In a pre-clinical PAD model, Luyt et al. ([@B81]) demonstrated that endothelin, antagonists, bosentan, and darusentan (LU13525) increased tissue blood flow measured by laser Doppler perfusion imaging. de Haro Miralles et al. ([@B32]) examined plasma levels of endothelin and showed that endothelin levels were increased in patients with intermittent claudication compared to non-PAD controls. Just as importantly patients with the most severe form of PAD, CLI, did not demonstrate elevated levels of endothelin, which suggests that an elevation of endothelin is specific to the pathophysiology of intermittent claudication and not all forms of PAD. The original indication of zibotentan was in oncology and pulmonary artery hypertension. The reuse of an endothelin receptor antagonists in PAD patients with intermittent claudication is now in a Phase II clinical trial; the details of the clinical trial of zibotentan are provided in ClinicalTrials.gov <https://clinicaltrials.gov/ct2/show/NCT01890135?term=NCT01890135&rank=1>.

### Case II: Carvedilol targeting NPPB

Carvedilol has anti-inflammatory and pro-angiogenic effects in chronic ischemic cardiomyopathy (Le et al., [@B75]). Carvedilol showed improvement of myocardial flow and reduction of inflammation in the canine model of multivessel cardiomyopathy. The anti-inflammatory cytokine IL-10, which inhibits inflammatory cytokines such as TNFα, IL-1, IL-6, IL-8, and IL-12, was up-regulated in the carvedilol-treated animals. In the PAD microarray data, the inflammatory cytokine IL-8 was up-regulated as found in Masud et al. ([@B83]) and Croner et al. ([@B28]). Though beta-blockers are commonly used in patients with PAD, currently there are no specific clinical trials for carvedilol being compared to placebo or other beta-blockers in PAD patients.

### Case III: Maraviroc targeting CCR5

Maraviroc is an HIV drug targeting CCR5, which is involved in the inflammation pathway (Francisci et al., [@B43]). Therefore, maraviroc could have anti-inflammatory and anti-atherosclerosis effects, and become a potential repositioning drug in PAD. Croner et al. ([@B28]) show the up-regulation of CCR5 in microarrays from the human femoral artery in PAD. CCR5 inhibitor maraviroc also blocks cell migration and metastasis, but not directly affects the angiogenesis pathway in triple negative breast cancer cell lines (Lee et al., [@B76]). Currently there are no clinical trials for maraviroc in PAD patients.

Limitations of computational drug repositioning approaches
----------------------------------------------------------

There are several limitations by the computational approaches to predict the repositioning drugs in PAD. First, PAD is a complex disease caused by many risk factors and classified by different stages of diseases. Our methods cannot predict the repositioning drugs based on various conditions in PAD patients. Second, the current available clinical trials based on these predicted repositioning drugs in PAD patients are very limited. The available gene expression dataset in human PAD and mouse PAD model is limited. It is difficult to validate our predictions by current clinical trials and available microarray data. Third, the pro-angiogenic and anti-inflammatory drug-target networks cannot directly link the drugs to PAD based on the current physiological evidence in PAD. The value of the computational drug repositioning might be limited for clinical trial design.

Conclusions {#s5}
===========

Our study provides comprehensive predictions of potential pro-angiogenic and anti-inflammatory drugs and drug targets for PAD patients. Based on the protein-protein interaction network PADPIN, we collected the binary relations between FDA-approved drugs and genes annotated in PADPIN. By gathering FDA-approved drugs, these predictions form a basis for further validation and future translational research in PAD.
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